147 related articles for article (PubMed ID: 32020481)
1. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway.
Gao Y; Li L; Zheng H; Zhou C; Chen X; Hao B; Cao Y
J Neurooncol; 2020 Feb; 146(3):513-521. PubMed ID: 32020481
[TBL] [Abstract][Full Text] [Related]
2. KIF3C Promotes Proliferation, Migration, and Invasion of Glioma Cells by Activating the PI3K/AKT Pathway and Inducing EMT.
Gao Y; Zheng H; Li L; Zhou C; Chen X; Zhou X; Cao Y
Biomed Res Int; 2020; 2020():6349312. PubMed ID: 33150178
[TBL] [Abstract][Full Text] [Related]
3. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
Immunobiology; 2024 May; 229(3):152802. PubMed ID: 38569452
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of miR-770 indicates a favorable prognosis and suppresses tumorigenesis by modulating PI3K-AKT pathway in glioma.
Feng FQ; Liu GS; Li JC; Chen LZ
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2870-2879. PubMed ID: 31002138
[TBL] [Abstract][Full Text] [Related]
5. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
Yang J; Liao D; Wang Z; Liu F; Wu G
J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
[TBL] [Abstract][Full Text] [Related]
7. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Sun Z; Xue H; Wei Y; Wang C; Yu R; Wang C; Wang S; Xu J; Qian M; Meng Q; Li G
Clin Sci (Lond); 2019 May; 133(10):1167-1184. PubMed ID: 31076460
[TBL] [Abstract][Full Text] [Related]
8. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.
Zhu Y; Zhang X; Qi L; Cai Y; Yang P; Xuan G; Jiang Y
Oncotarget; 2016 Mar; 7(12):14429-40. PubMed ID: 26894862
[TBL] [Abstract][Full Text] [Related]
9. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway.
Li Y; Ma X; Wang Y; Li G
Biomed Pharmacother; 2017 Sep; 93():435-443. PubMed ID: 28666210
[TBL] [Abstract][Full Text] [Related]
10. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
12. LncRNA CAI2 Contributes to Poor Prognosis of Glioma through the PI3K-Akt Signaling Pathway.
Jiang Y; Zhang J; Yu S; Zheng L; Shen Y; Ju W; Lin L
Comb Chem High Throughput Screen; 2024; 27(3):420-427. PubMed ID: 37211840
[TBL] [Abstract][Full Text] [Related]
13. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
17. The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway.
Zhang T; Ji D; Wang P; Liang D; Jin L; Shi H; Liu X; Meng Q; Yu R; Gao S
Cancer Lett; 2018 Feb; 415():151-163. PubMed ID: 29233656
[TBL] [Abstract][Full Text] [Related]
18. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
19. SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway.
Liu C; Wu H; Li Y; Shen L; Yu R; Yin H; Sun T; Sun C; Zhou Y; Du Z
J Neurooncol; 2017 Nov; 135(2):263-272. PubMed ID: 28887597
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
